Over the past three decades, nanoscience has offered a unique solution for reducing the systemic toxicity of chemotherapy drugs and for increasing drug therapeutic efficiency. However, the poor accumulation and pharmacokinetics of nanoparticles are some of the key reasons for their slow translation into the clinic. The is intimately linked to the non-biological nature of nanoparticles and the aberrant features of solid cancer, which together significantly compromise nanoparticle delivery. New findings on the unique properties of tumors and their interactions with nanoparticles and the human body suggest that, contrary to what was long-believed, tumor features may be more mirage than miracle, as the enhanced permeability and retention based efficacy is estimated to be as low as 1%. In this review, we highlight the current barriers and available solutions to pave the way for approved nanoformulations. Furthermore, we aim to discuss the main solutions to solve inefficient drug delivery with the use of nanobioengineering of nanocarriers and the tumor environment. Finally, we will discuss the suggested strategies to overcome two or more biological barriers with one nanocarrier. The variety of design formats, applications and implications of each of these methods will also be evaluated.
(1) Background: Mounting evidence supports the idea that one of the most critical agents in controlling gene expression could be long non-coding RNAs (lncRNAs). Upregulation of lncRNA is observed in the different processes related to pathologies, such as tumor occurrence and development. Among the crescent number of lncRNAs discovered, FLVCR1-AS1 and FBXL19-AS1 have been identified as oncogenes in many cancer progression and prognosis types, including cholangiocarcinoma, gastric cancer, glioma and glioblastoma, hepatocellular carcinoma, lung cancer, ovarian cancer, breast cancer, colorectal cancer, and osteosarcoma. Therefore, abnormal FBXL19-AS1 and FLVCR1-AS1 expression affect a variety of cellular activities, including metastasis, aggressiveness, and proliferation; (2) Methods: This study was searched via PubMed and Google Scholar databases until May 2022; (3) Results: FLVCR1-AS1 and FBXL19-AS1 participate in tumorigenesis and have an active role in impacting several signaling pathways that regulate cell proliferation, migration, invasion, metastasis, and EMT; (4) Conclusions: Our review focuses on the possible molecular mechanisms in a variety of cancers regulated by FLVCR1-AS1 and FBXL19-AS1. It is not surprising that there has been significant interest in the possibility that these lncRNAs might be used as biomarkers for diagnosis or as a target to improve a broader range of cancers in the future.
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary development in the field of cancer immunotherapy, offering a targeted approach to combat various hematologic malignancies. In this treatment, the patient’s genetically modified T cells are extracted and transformed to produce chimeric antigen receptors (CARs) that are exclusive to cancer cells. These altered T cells identify, attach to, and destroy cancer cells when they are reinfused back into the patient, offering a customized course of therapy. While the CAR T-cell therapy’s clinical success has been most evident in cases of acute lymphoblastic leukemia and certain types of lymphomas, ongoing research aims to extend its applicability to solid tumors. Despite its promise, challenges like cytokine release syndrome and the high cost of treatment remain. Nonetheless, CAR T-cell therapy heralds a new era in cancer treatment, offering a potentially curative approach for patients with otherwise refractory diseases.
23 September 2025 in Bioinspired, Biomimetic and Nanobiomaterials
Nanomedicine has emerged as a promising strategy to mitigate the drawbacks of chemotherapy by enabling targeted drug delivery. Protein nanocages, particularly ferritin, have gained attention due to their unique structural properties and biocompatibility. Herein, the development and characterization of truncated maize ferritin 1 (T-ZmFer1) nanocages for enhanced drug delivery are reported, achieved by removing the E-helix through excision of 17 amino acids from the C-terminus of the protein. T-ZmFer1 was expressed in Escherichia coli Bl21 (DE3) and optimized to enhance soluble protein expression. Purified T-ZmFer1 nanocages exhibited a size of 18.17 nm with a zeta potential of −19.9 mV, indicating well-defined structural characteristics. Drug encapsulation studies revealed a significant increase in encapsulation capacity for T-ZmFer1 nanocages compared to intact ZmFer1 nanocages, with a loading efficiency of ≈76 DOX/protein. Moreover, in vitro drug release profiles demonstrated controlled release kinetics for T-ZmFer1 nanocages, with pH-dependent release behavior. Cytotoxicity assays in SKBR3 cells showed comparable efficacy between DOX-loaded T-ZmFer1 and ZmFer1 nanocages, with T-ZmFer1 nanocages exhibiting superior cytotoxicity at 1 μM DOX concentration. This study underscores the potential of T-ZmFer1 nanocages as versatile drug delivery systems for cancer therapy, offering enhanced biocompatibility and therapeutic efficacy, thus contributing to the advancement of nanomedicine.